Native high-density lipoproteins inhibit platelet activation via scavenger receptor BI. Role of negatively charged phospholipids

Atherosclerosis

Volumn 215, Issue 2, 2011, Pages 374-382

  Brodde, Martin F ^a   Korporaal, Suzanne J A ^b   Herminghaus, Grazyna ^a   Fobker, Manfred ^a   Van Berkel, Theo J C ^b   Tietge, Uwe J F ^c   Robenek, Horst ^d   Van Eck, Miranda ^b   Kehrel, Beate E ^a   Nofer, Jerzy Roch ^a,e  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b LEIDEN UNIVERSITY   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d Leibniz Institute for Arteriosclerosis Research   (Germany)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

High density lipoproteins (HDL); Platelets; Scavenger receptor type I (SR BI)

Indexed keywords

ALBUMIN; CD36 ANTIGEN; DIACYLGLYCEROL; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN 3; LIPOSOME; PADGEM PROTEIN; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLSERINE; PROTEIN KINASE C; SCAVENGER RECEPTOR A; SCAVENGER RECEPTOR BI; THROMBIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CALCIUM TRANSPORT; CONTROLLED STUDY; ENZYME ACTIVATION; FIBRIN FORMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

ANIMALS; ANTIGENS, CD36; BLOOD PLATELETS; HUMANS; LIPOPROTEINS, HDL2; LIPOPROTEINS, HDL3; LIPOSOMES; MICE; MICE, KNOCKOUT; PHOSPHATIDYLINOSITOLS; PHOSPHATIDYLSERINES; PHOSPHOLIPIDS; PLATELET ACTIVATION;

EID: 79953036425     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.12.026     Document Type: Article

References (36)

1. Weber C. Platelets and chemokines in atherosclerosis: partners in crime. Circ Res 2005, 96:612-616.
2. Lindemann S., Krämer B., Daub K., Stellos K., Gawaz M. Molecular pathways used by platelets to initiate and accelerate atherogenesis. Curr Opin Lipidol 2007, 18:566-573.
3. Siegel-Axel D., Daub K., Seizer P., Lindemann S., Gawaz M. Platelet lipoprotein interplay: trigger of foam cell formation and driver of atherosclerosis. Cardiovasc Res 2008, 78:8-17.
4. Gawaz M., Neumann F.J., Ott I., Schiessler A., Schömig A. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 1996, 93(2):229-237.
5. Ott I., Neumann F.J., Gawaz M., Schmitt M., Schömig A. Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation 1996, 94:1239-1246.
6. Friedman R.J., Stemernman M.D., Wenz B., et al. The effect of thrombocytopenia on experimental atherosclerotic lesion formation in rabbits. J Clin Invest 1977, 60:1191-1201.
7. Korporaal S.J.A., Akkerman J.W. Platelet activation by low density lipoproteins and high density lipoproteins. Pathophysiol Haemost Thromb 2006, 35:270-280.
8. Koller E., Volf I., Gurvitz A., Koller F. Pathophysiol Haemost Thromb 2006, 35:322-345.
9. Ageno W., Becattini C., Brighton T., Selby R., Kamphuisen P.W. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 2008, 117:93-102.
10. Naqvi T.Z., Shah P.K., Ivey P.A., et al. Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation. Am J Cardiol 1999, 84:1011-1017.
11. Nofer J.R., Walter M., Kehrel B., et al. HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1,2-diacylglycerol and inositol 1,4,5-tris-phosphate. Arterioscler Thromb Vasc Biol 1998, 18:861-869.
12. Nofer J.-R., Tepel M., Kehrel B., et al. High density lipoproteins enhance the Na+/H+ antiport in human platelets. Thromb Haemost 1996, 75:635-641.
13. Rigotti A., Trigatti B.L., Penman M., Rayburn H., Herz J., Krieger M. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc Natl Acad Sci U S A 1997, 94:12610-12615.
14. Febbraio M., Abumrad N.A., Hajjar D.P., et al. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J Biol Chem 1999, 274:19055-19062.
15. Havel R.J., Eder H., Bragdon J.H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1995, 3:1345-1353.
16. Schmitz G., Wulf G., Brüning T., Assmann G. Flow-cytometric determination of high-density-lipoprotein binding sites on human leukocytes. Clin Chem 1987, 33:2195-2203.
17. Imber M.J., Pizzo S.V., Johnson W.J., Adams D.O. Selective diminution of the binding of mannose by murine macrophages in the late stages of activation. J Biol Chem 1982, 257:5129-5135.
18. Bligh E.G., Dyer W.J. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959, 37:911-917.
19. Silversand C., Haux C. Improved high-performance liquid chromatographic method for the separation and quantification of lipid classes: application to fish lipids. J Chromatogr B Biomed Sci Appl 1997, 703:7-14.
20. Xia Z., Wong T., Liu Q., Kasirer-Friede A., Brown E., Frojmovic M.M. Optimally functional fluorescein isothiocyanate (FITC)-labelled fibrinogen for quantitative studies of binding to activated platelets and platelet aggregation. Br J Haematol 1996, 93:204-214.
21. Gruchalla R.S., Dinh T.T., Kennerly D.A. An indirect pathway of receptor-mediated 1,2-diacylglycerol formation in mast cells I. IgE receptor-mediated activation of phospholipase D. J Immunol 1990, 144:2334-2342.
22. Murao K., Terpstra V., Green S.R., Kondratenko N., Steinberg D., Quehenberger O. Characterization of CLA-1, a human homologue of rodent scavenger receptor BI, as a receptor for high density lipoprotein and apoptotic thymocytes. J Biol Chem 1997, 272:17551-17557.
23. Rigotti A., Acton S.L., Krieger M. The class B scavenger receptors SR-BI and CD36 are receptors for anionic phospholipids. J Biol Chem 1995, 270:16221-16224.
24. Acton S.L., Scherer P.E., Lodish H.F., Krieger M. Expression cloning of SR-BI, a CD36-related class B scavenger receptor. J Biol Chem 1994, 269:21003-21009.
25. Koller E., Koller F., Binder B.R. Purification and identification of the lipoprotein-binding proteins from human blood platelet membrane. J Biol Chem 1989, 264:12412-12418.
26. Pedreño J., de Castellarnau C., Masana L. Platelet HDL(3) binding sites are not related to integrin alpha(IIb) beta(3) (GPIIb-IIIa). Atherosclerosis 2001, 154:23-29.
27. Desai K., Bruckdorfer K.R., Hutton R.A., Owen J.S. Binding of apoE-rich high density lipoprotein particles by saturable sites on human blood platelets inhibits agonist-induced platelet aggregation. J Lipid Res 1989, 30:831-840.
28. Riddell D.R., Vinogradov D.V., Stannard A.K., Chadwick N., Owen J.S. Identification and characterization of LRP8 (apoER2) in human blood platelets. J Lipid Res 1999, 40:1925-1930.
29. Higashihara M., Kinoshita M., Kume S., Teramoto T., Kurokawa K. Inhibition of platelet function by high-density lipoprotein from a patient with apolipoprotein E deficiency. Biochem Biophys Res Commun 1991, 181:1331-1336.
30. Imachi H., Murao K., Cao W., et al. Expression of human scavenger receptor B1 on and in human platelets. Arterioscler Thromb Vasc Biol 2003, 23:898-904.
31. Valiyaveettil M., Kar N., Ashraf M.Z., Byzova T.V., Febbraio M., Podrez E.A. Oxidized high-density lipoprotein inhibits platelet activation and aggregation via scavenger receptor BI. Blood 2008, 111:1962-1971.
32. Assinger A., Schmid W., Eder S., Schmid D., Koller E., Volf I. Oxidation by hypochlorite converts protective HDL into a potent platelet agonist. FEBS Lett 2008, 582:778-784.
33. Podrez E.A., Byzova T.V., Febbraio M., et al. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med 2007, 13:1086-1095.
34. Ardlie N.G., Selley M.L., Simons L.A. Platelet activation by oxidatively modified low density lipoproteins. Atherosclerosis 1989, 76:117-124.
35. Takahashi Y., Chiba H., Matsuno K., et al. Native lipoproteins inhibit platelet activation induced by oxidized lipoproteins. Biochem Biophys Res Commun 1996, 222:453-459.
36. Calkin A.C., Drew B.G., Ono A., et al. Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation 2009, 120:2095-2104.